



Mesothelioma: Diagnosis and Therapy

Guest Editor:

Dr. Avinash Aujayeb

1. Respiratory Medicine
Department, Northumbria
Healthcare NHS Foundation
Trust, Cramlington NE22 9EH, UK
2. Department of Respiratory
Medicine, North Tyneside General
Hospital, North Tyneside,
Newcastle NE298NH, UK

Deadline for manuscript
submissions:

30 November 2025

Message from the Guest Editor

Dear Colleagues,

Malignant mesothelioma is a rare incurable cancer that is predominantly related to asbestos exposure. There have been numerous advances in this field, including innovations in diagnostics, the development of enhanced staging and immunotherapy treatment, and novel evidence regarding surgical treatments and intrapleural therapy. This Special Issue therefore welcomes the submission of articles related to these topics.

We are pleased to invite you to contribute to this Special Issue on mesothelioma with original research articles and reviews. The research included in this Special Issue may present updated diagnostic methods, novel treatment options and debates around surgical treatment. I look forward to receiving your contributions.

Dr. Avinash Aujayeb
Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)